Case Study: Fortune 500 Drug & Device Development Company eliminates guesswork in security validation with SafeBreach

Fortune 500 Drug & Device Development Company Implements SafeBreach for Security Control Validation

Fortune 500 Drug & Device Development Company, a global clinical research organization handling large volumes of sensitive trial data, struggled to validate whether its many security controls actually worked. Traditional penetration tests were time-consuming (taking more than 12 months to plan, execute, and remediate), incomplete, and inconsistent, leaving the security team reliant on guesswork. To gain continuous, data-driven validation, the company implemented the SafeBreach breach and attack simulation (BAS) platform.

SafeBreach automated safe, continuous execution of real-world attack playbooks (infiltration, lateral movement, exfiltration), enabling the team to validate controls, benchmark risk, and rapidly assess acquired environments. With SafeBreach the company gained clear, objective evidence to consolidate anti‑malware tools, shorten months‑long testing cycles to continuous assessment, improve operational efficiency and cost control through automation, and strengthen customer safeguards and confidence in their security posture.